Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...
Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...
Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., shared new data ...
Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...
AbbVie (NYSE: ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monot...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...
Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...
© 2025 Biopharma Boardroom. All Rights Reserved.
